Abstract

Semaglutide (Wegovy) is a GLP‐1 analogue indicated as an adjunct to diet and physical activity for weight management in adults who are overweight or obese. This article discusses its efficacy, adverse effects and place in therapy.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call